Immunotherapy and chemotherapy for borderline resectable esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial is testing a new drug called QL1706 (an immunotherapy that helps your immune system fight cancer) combined with chemotherapy for a type of esophageal cancer that is advanced but may still be surgically removed. The goal is to see if this combination can shrink the tumor and improve outcomes before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with esophageal squamous cell carcinoma, a common type of esophageal cancer.
- Your cancer is at a stage where it is locally advanced (cT4a), or has spread to nearby lymph nodes in a way that is still considered borderline resectable.
- You have not received any prior anti-cancer treatment for this condition.
- You are at least 18 years old.
- You are able to take care of yourself and are not confined to bed (ECOG score 0-1).
- You do not have certain conditions that would make the study unsafe, such as autoimmune disease, current steroid use, lung disease, or prior treatment with immune checkpoint inhibitors.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (adebrelimab), an immune-boosting agent (thymalfasin), and standard chemotherapy given before surgery for esophageal cancer. The goal is to see if this combination can shrink the tumor and improve outcomes after surgery.
This trial tests whether combining a new immunotherapy drug (adebrelimab) with standard chemotherapy can help shrink borderline resectable esophageal squamous cell carcinoma before surgery. The goal is to make tumors easier to remove and improve survival.
This trial tests a treatment approach that combines low-dose radiation with immunotherapy and chemotherapy for people with esophageal cancer that is hard to remove with surgery. The goal is to shrink the tumor enough to make surgery possible, which could improve outcomes.
This trial tests whether adding an immunotherapy drug (QL1706) to standard chemotherapy before surgery can improve outcomes for people with esophageal cancer that can be removed. The goal is to see if the combination shrinks tumors more effectively and is safe.
This study tests a new treatment for people with locally advanced esophageal cancer that did not respond to initial chemotherapy and immunotherapy. The goal is to see if the study drug can shrink or control the cancer when surgery is not an option.
This trial tests a new immunotherapy drug, QL1706, given before surgery for esophageal squamous cell cancer. The goal is to see if it helps shrink tumors and improve outcomes for patients who are healthy enough for the treatment.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.